Tarsus Pharmaceuticals, Inc. TARS Unvested
Unvested at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s unvested.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s unvested?
- Tarsus Pharmaceuticals, Inc. (TARS) reported unvested of $37.56M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s unvested changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s unvested decreased by 0.6% year-over-year, from $37.8M to $37.56M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s unvested?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s unvested has grown at a 4.4% compound annual growth rate (CAGR), from $51.99M to $64.59M.
- What does unvested mean?
- This metric tracks the specific portion of share-based compensation awards that remain unvested as of the reporting date. It is used to evaluate the remaining service period for employees and the potential future expense recognition associated with these equity grants.